Title: Nutritional Impact of Ivacaftor treatment in 1 to 2 Year Old Children with CF Gating Mutations

Short Title: Ivacaftor in 1 to 2 Year Old Children with CF

Regulatory Sponsor:

eIRB Number: 18-015299

Protocol Version Date: 8/21/2018

Amendment 1 Date: Amendment 3 Date:

Amendment 2 Date: Amendment 4 Date:

Sponsor

Vertex Pharmaceuticals
50 Northern Ave.
Boston, MA 02210

Principal Investigator

Virginia A. Stallings, MD
2716 South Street, Room 14473
Philadelphia, PA, 19146
Phone: 267.425.1633
email: stallingsv@email.chop.edu
TABLE OF CONTENTS

Table of Contents ........................................................................................................................................ ii
Abbreviations and Definitions of Terms ........................................................................................................ iv
Abstract ....................................................................................................................................................... iv
Protocol Synopsis ....................................................................................................................................... vi

1  BACKGROUND INFORMATION AND RATIONALE ........................................................................... 1
   1.1  INTRODUCTION ............................................................................................................................ 1
   1.2  COMPLIANCE STATEMENT ........................................................................................................... 3

2  STUDY OBJECTIVES ............................................................................................................................ 3
   2.1  PRIMARY OBJECTIVE (OR AIM) .................................................................................................... 4
   2.2  SECONDARY OBJECTIVES (OR AIM) .......................................................................................... 4
   2.3  EXPLORATORY AIMS ................................................................................................................. 4

3  INVESTIGATIONAL PLAN ..................................................................................................................... 4
   3.1  GENERAL SCHEMA OF STUDY DESIGN ....................................................................................... 4
       3.1.1  Screening Phase .................................................................................................................. 4
       3.1.2  Study Enrollment Phase ...................................................................................................... 4
       3.1.3  Follow-up Phase .................................................................................................................. 4
   3.2  STUDY DURATION, ENROLLMENT AND NUMBER OF SITES ..................................................... 5
       3.2.1  Duration of Study Participation ............................................................................................ 5
       3.2.2  Total Number of Study Sites/Total Number of Subjects Projected ... Error! Bookmark not defined.
   3.3  STUDY POPULATION ................................................................................................................. 5
       3.3.1  Inclusion Criteria .................................................................................................................. 5
       3.3.2  Exclusion Criteria ................................................................................................................ 5

4  STUDY PROCEDURES .......................................................................................................................... 6
   4.1  SCREENING/CONSENT VISIT (VISIT 1) .................................................................................... 6
   4.2  OBSERVATIONAL PERIOD ......................................................................................................... 6
       4.2.1  Visit 1 .................................................................................................................................... 6
       4.2.2  Visit 2 .................................................................................................................................... 7
       4.2.3  Visit 3 .................................................................................................................................... 8
   4.3  UNSCHEDULED VISITS .............................................................................................................. 8
   4.4  SUBJECT COMPLETION/WITHDRAWAL ................................................................................... 9

5  STUDY EVALUATIONS AND MEASUREMENTS .............................................................................. 9
   5.1  SCREENING AND MONITORING EVALUATIONS AND MEASUREMENTS ......................... 9
       5.1.1  Medical Record Review ...................................................................................................... 9
       5.1.2  Laboratory Evaluations ...................................................................................................... 9
       5.1.3  Study Assessments ............................................................................................................. 9
   5.3  SAFETY EVALUATION .............................................................................................................. 11

6  STATISTICAL CONSIDERATIONS ................................................................................................. 11
   6.1  STATISTICAL METHODS ............................................................................................................. 11
       6.1.1  ANALYSIS OF PRIMARY AND SECONDARY ENDPOINTS ........................................... 11
   6.2  SAMPLE SIZE AND POWER ...................................................................................................... 12

7  STUDY MEDICATION (STUDY DEVICE OR OTHER STUDY INTERVENTION) ....................... 13
   7.1  DESCRIPTION ............................................................................................................................. 13
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>AE</td>
<td>Adverse event</td>
</tr>
<tr>
<td>BMI</td>
<td>Body mass index</td>
</tr>
<tr>
<td>BMIZ</td>
<td>BMI Z score</td>
</tr>
<tr>
<td>CF</td>
<td>Cystic fibrosis</td>
</tr>
<tr>
<td>CFTR</td>
<td>Cystic fibrosis transmembrane conductance regulator</td>
</tr>
<tr>
<td>CHPS</td>
<td>Center for Human Phenomic Science</td>
</tr>
<tr>
<td>CYP</td>
<td>Cytochrome P450</td>
</tr>
<tr>
<td>DXA</td>
<td>Dual energy x-ray absorptiometry</td>
</tr>
<tr>
<td>SEE</td>
<td>Sleeping energy expenditure</td>
</tr>
<tr>
<td>FFM</td>
<td>Fat free mass</td>
</tr>
<tr>
<td>FM</td>
<td>Fat mass</td>
</tr>
<tr>
<td>HAZ</td>
<td>Height Z score</td>
</tr>
<tr>
<td>Ivacaftor</td>
<td>Kalydeco, VX-770</td>
</tr>
<tr>
<td>NDS</td>
<td>Nutrition data system</td>
</tr>
<tr>
<td>PHI</td>
<td>Personal health information</td>
</tr>
<tr>
<td>SAE</td>
<td>Serious adverse event</td>
</tr>
<tr>
<td>SEE</td>
<td>Sleeping energy expenditure</td>
</tr>
<tr>
<td>ucOC%</td>
<td>Undercarboxylated osteocalcin</td>
</tr>
<tr>
<td>WAZ</td>
<td>Weight Z score</td>
</tr>
</tbody>
</table>
ABSTRACT

Context: Ivacaftor is a novel FDA approved therapy for patients with CF and gating mutations who are 2 years and older. Clinical studies are in progress for an additional age group of children, ages 1 to 2, and FDA review is anticipated soon. Our Investigator Initiated Study is designed to evaluate the nutritional, growth and GI impact of ivacaftor treatment for this unique younger (1 to 2 years) patient cohort and for whom FDA approval for treatment is anticipated in the near future. This proposal directly extends our previous highly informative nutrition and weight gain investigation of ivacaftor treatment in the older patient cohort.

Objectives: The primary aims of the study are to evaluate the impact of 12 weeks of ivacaftor treatment in 1 to 2 year old subjects with CF and gating mutations on sleeping energy expenditure, growth status and gut health and function in n=18 children with protocol evaluations at baseline (pre-treatment) and 6 and 12 weeks after clinically prescribed ivacaftor treatment has begun. Other outcomes of significant clinical interest in young patients with CF will be explored. All subjects will be evaluated at The Children's Hospital of Philadelphia, and will be recruited both regionally and nationally to ensure timely enrollment.

Study Design: Observational prospective study with evaluations before and after 12 weeks of ivacaftor treatment. An interim assessment at 6 weeks will also be included.

Setting/Participants: Eighteen subjects ages 1 to 2 years of age cystic fibrosis and CFTR gating mutations who are in a general state of good health from cystic fibrosis centers in US and Canada.

Study Interventions and Measures: Subjects will be evaluated before and after ivacaftor treatment for sleeping energy expenditure, BMI Z score, gut health and function as indicated by plasma fatty acids, fecal elastase and fecal calprotectin. Dietary intake, growth status and velocity, and serum fat soluble vitamins, bile acids and calprotectin will also be assessed.
PROTOCOL SYNOPSIS

<table>
<thead>
<tr>
<th>Study Title</th>
<th>Nutritional Impact of Ivacaftor Treatment in 1 to 2 Year Old Children with CF Gating Mutations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Funder</td>
<td>Vertex Pharmaceutical and CHOP Center for Human Phenomic Science and Nutrition Center</td>
</tr>
</tbody>
</table>
| Study Rationale                                 | Cystic fibrosis (CF) is a genetic disease caused by mutations in the gene encoding the CF transmembrane conductance regulator (CFTR), a chloride channel in many types of cells. Most CF mutations either reduce the number of CFTR channels at the cell surface (synthesis and processing mutations) or impair channel function (gating or conductance mutations). Ivacaftor (Kalydeco®, Vertex Pharmaceuticals Inc.) was the first of a new class of drugs that improved CFTR gating dysfunction. For such mutations (G551D, G178R, S549N, S549R, G551S, G970R, G1244E, S1251N, S1255P, G1349D) that permit CFTR expression at the cell membrane but compromise its activity, ivacaftor increases the probability that the chloride channel is open and active. In randomized, double-blind, placebo controlled trials, ivacaftor treatment in individuals (ages 6 to adulthood) with at least one G551D mutation resulted in clinically significant improvements in weight and body mass index (BMI), pulmonary function, and patient reported quality of life outcomes (QOL). Lung function and weight changes occurred over eight weeks, then plateaued and were sustained over 48 weeks. In the initial trials ivacaftor treatment in individuals with at least one G551D mutation resulted in rapid and sustained weight gain, increased FEV1%, decreased pulmonary exacerbations, decreased sweat chloride concentration reflective of increased CFTR activity, and improved patient reported health-related QOL outcomes. Ivacaftor has shown similar benefit in younger children and has been approved for use in 2 to 5 year old children. Ivacaftor was found to be safe and effective in 33 children in the KIWI study completed 24 weeks of treatment in the KIWI study, with significant reductions in sweat chloride concentration, and an average increase in weight Z score of 0.2±0.3 and BMI z score of 0.4±0.4. Some exocrine pancreatic function restoration was demonstrated in these young children, as Davies et al. In our recent longitudinal observational study of 23 subjects (ages 5 to 61 years), we identified several mechanisms for weight gain with 3-month ivacaftor treatment including decreased resting energy expenditure (REE), gut inflammation and dietary fat malabsorption, resulting in a positive energy balance and weight gain. Weight gain in this study was 2.5 kg and was associated with a significant decrease in REE percent predicted of 5.5%, and in fecal calprotectin of 30 ug/g stool, a measure of gut inflammation. Several outcomes related to improved energy balance are considered in this proposal. Building on our results in older
subjects, we will once again focus on the importance of determining the effect of ivacaftor treatment on clinically important non-pulmonary outcomes. Our primary aim in this study of young 1 to 2 year old children is to determine if 12-week ivacaftor treatment results in decreased sleeping energy expenditure (REE) and improved growth status by BMI Z score. Our secondary aim is to determine improvement in gut health and function associated with fat digestion, including increased total plasma fatty acids and fecal elastase, and decreased fecal calprotectin. Exploratory aims include investigating the impact of ivacaftor treatment on dietary intake, length, weight and head circumference status and growth velocity, and on serum fat soluble vitamins, bile acids and calprotectin.

Study Objective(s)

We propose a longitudinal study design to determine whether 12 weeks of treatment with ivacaftor results in improvement in sleeping energy expenditure (SEE), growth status as BMI Z score, and gut health and function in \( n=18 \) children ages 1 to 2 years with at least one CFTR gating mutation. We anticipate that these changes will accompany meaningful improvements in dietary intake, growth status and growth velocity, and serum fat soluble vitamins, bile acids and serum calprotectin in these young children.

**PRIMARY AIMS**

H1: Ivacaftor treatment will result in a significant reduction in SEE as percent predicted over 12 weeks compared to baseline, thereby increasing the energy available for weight gain and physical activity.

H2: Ivacaftor treatment will result in significantly increased BMI Z score over 12 weeks compared to baseline.

**SECONDARY AIMS**

H3: Ivacaftor treatment will result in significantly improved gut health and function resulting in better dietary fat absorption as indicated by increased total plasma fatty acids and fecal elastase and decreased fecal calprotectin over 12 weeks compared to baseline.

**EXPLORATORY AIMS**

To determine the impact of ivacaftor treatment over 12 weeks compared to baseline in:

- Dietary intake of calories and percent calories from fat
- Growth status for length, weight, head circumference and growth velocity
- Serum fat soluble vitamins A, D, E and K, bile acids, and serum calprotectin

**Study Design**

We propose a longitudinal study design to assess sleeping energy expenditure, improvement in BMI Z score, and improved gut health and function in \( n=18 \) children ages 1 to 2 years with CF with a
Inclusion and Exclusion:

**Inclusion Criteria**
- Cystic fibrosis with at least one CFTR gating mutation of these ten (G551D, G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P, G1349D, or R117H) approved for treatment
- Age: 1 to 2 years of age
- In their usual state of good health
- A clinical decision has been made for subject to begin ivacaftor treatment
- Family committed to the 4 to 6 month study protocol with visits to CHOP that will last 2 or 3 days for the baseline visit (Visit 1) prior to ivacaftor and the 12 week visit (Visit 3) after clinically prescribed ivacaftor treatment has begun, and will last 2 days for the 6 week visit (Visit 2) after ivacaftor treatment has begun.
- Note that if ivacaftor is approved by the FDA for 1 to 2 year old children for the additional 28 CFTR mutations known to be responsive to ivacaftor potentiation, these will also be considered. With our limited samples size, the mutations that have shown the strongest improvement with treatment will be given priority for enrollment.

**Exclusion Criteria**
- On parenteral nutrition
- Use of any inhibitors or inducers of cytochrome P450 (CYP) 3A
- Liver function tests elevated above 3x the reference range for age and sex
- Other illness affecting growth or nutritional status
- Other contraindications described for ivacaftor therapy

<table>
<thead>
<tr>
<th>Number Of Subjects</th>
<th>18</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study Duration</td>
<td>Each subject’s participation will last 4 to 6 months</td>
</tr>
<tr>
<td></td>
<td>The entire study is expected to last 15 months</td>
</tr>
<tr>
<td>Study Phases</td>
<td><strong>Screening:</strong> screening for eligibility and obtaining consent</td>
</tr>
<tr>
<td></td>
<td><strong>Baseline:</strong> baseline study visit at CHOP</td>
</tr>
<tr>
<td></td>
<td><strong>Follow up:</strong> 6 week visit at CHOP after confirmation of timing of the start of clinically prescribed ivacaftor treatment (±2 week window)</td>
</tr>
<tr>
<td></td>
<td><strong>Follow up:</strong> 12 week visit at CHOP after confirmation of timing of the start of clinically prescribed ivacaftor treatment (±2 week window)</td>
</tr>
<tr>
<td>Safety Evaluations</td>
<td>As part of safety assessment, a serum comprehensive metabolic panel including the ALT and AST liver enzymes, complete blood</td>
</tr>
</tbody>
</table>
count and serum pre-albumin will be assessed (CHOP Clinical Laboratory).

Dosing will likely be interrupted by the CF clinical care team in subjects with ALT or AST of greater than 5 times the upper limit of normal (ULN).

Subjects will be asked about all adverse events at the 6 and 12 week protocol visits and during the bi-weekly phone calls, and rated by intensity (mild, moderate, severe). Serious adverse events will be reported as per various policies in a timely manner to CHOP IRB and CHPS.

**Statistical And Analytic Plan**

**Primary Aims:** The goals of the primary aims of this study are to determine whether ivacaftor treatment improves SEE and BMI Z score. **Secondary Aims:** The goal of the secondary aim is to determine whether ivacaftor improves gut health and function as measured by total plasma fatty acids, fecal elastase and fecal calprotectin (ug/g stool). Analysis of efficacy for the primary and secondary outcomes will be based on change from baseline (before treatment) in SEE% predicted (Schofield), BMI Z scores, total plasma fatty acids, fecal elastase and fecal calprotectin. The differences between baseline and 12 weeks continuous outcomes will initially be compared using paired-t-tests if continuous variables are normally distributed and nonparametric tests (Wilcoxon sign rank) if they are not. Subsequently, mixed effects longitudinal models will be performed to assess change over all three time points (baseline, 6 and 12 weeks), adjusting for potential covariates such as age, sex, and adherence to treatment. Chi-squared tests will be used for comparison of categorical variables before and after ivacaftor treatment. Using similar methods, exploratory analyses will examine improvement in dietary intake of calories and fat, in growth status (weight, length, and head circumference Z scores) and growth velocity (both absolute and Z scores), serum fat soluble vitamins, bile acids, and calprotectin.

**DATA AND SAFETY MONITORING PLAN**

Safety will be formerly monitored weekly by the study team. The study protocol will be carried out in accordance with OHRP guidelines and requirements. SAEs that are unanticipated, serious, and possibly related to the study intervention will be reported to the study sponsor, IRB, CHPS, and members of the research and clinical teams in accordance with requirements. Anticipated SAEs or those unrelated to the study intervention will be reported to the same individuals/entities in accordance with requirements. There will be ongoing collection of data on adverse events and compliance to the treatment protocol throughout the study by research staff and which will be summarized and reviewed monthly by the study Principal Investigator and the Study Team. Out of
range non-clinically significant laboratory data will be reviewed continually by the PI and the study team.
SCHEDULE OF STUDY PROCEDURES & STUDY TIMELINE

Table 1: Summary of Methods

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Pre-treatment</th>
<th>Post ivacaftor treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline</td>
<td>6 weeks</td>
</tr>
<tr>
<td>Energy Expenditure</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sleeping Energy Expenditure (SEE)</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Diet - 3-day Weighed Food Record</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Fecal Elastase I (pancreatic function)</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Fecal and Serum Calprotectin (inflammation)</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Biochemistry</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum Bile Acids</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Plasma Fatty Acids</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>CBC without differential</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Serum Pre-albumin</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Serum Retinol (Vitamin A)</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Serum a-tocopherol (Vitamin E)</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Serum 25(OH)D (Vitamin D)</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Serum undercarboxylated osteocalcin (Vitamin K)</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Anthropometry and Body Composition</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Length, Weight, BMI and Head Circumference</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Circumferences, Skinfolds</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>DXA Whole Body (FFM, FM, % Fat)</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Adherence to Ivacaftor, Enzymes, Medications</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Health History Questionnaire</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Safety</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum Comprehensive Metabolic Panel (ALT, AST)</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Adverse Events</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Study Timeline (n=18)

<table>
<thead>
<tr>
<th>Visit</th>
<th>Year 1 (2018-19)</th>
<th>Year 2 (2019)</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>July</td>
<td>Aug</td>
<td>Sept</td>
</tr>
<tr>
<td>Start-up</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Visit 1: Pre-treatment</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Visit 2: 6 wk Post-treatment</td>
<td>4</td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>Visit 3: 12 wk Post-treatment</td>
<td>4</td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>Visit Total</td>
<td>4</td>
<td>8</td>
<td>7</td>
</tr>
<tr>
<td>Data Analysis/Close</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
1 BACKGROUND INFORMATION AND RATIONALE

1.1 Introduction

Cystic fibrosis (CF) is a genetic disease caused by mutations in the gene encoding the CF transmembrane conductance regulator (CFTR), a chloride channel in many types of cells. Most CF mutations either reduce the number of CFTR channels at the cell surface (synthesis and processing mutations) or impair channel function (gating or conductance mutations). Ivacaftor (Kalydeco®, Vertex Pharmaceuticals Inc.) was the first of a new class of drugs that improved CFTR gating dysfunction\(^1^\)-\(^3\). For such mutations (G551D, G178R, S549N, S549R, G551S, G970R, G1244E, S1251N, S1255P, G1349D) that permit CFTR expression at the cell membrane but compromise its activity, ivacaftor increases the probability that the chloride channel is open and active. In randomized, double-blind, placebo controlled trials, ivacaftor treatment in individuals (ages 6 to adulthood) with at least one G551D mutation resulted in clinically significant improvements in weight and body mass index (BMI), pulmonary function, and patient reported quality of life outcomes (QOL)\(^3^,4\). Lung function and weight changes occurred over eight weeks, then plateaued and were sustained over 48 weeks.

In the initial trials ivacaftor treatment in individuals with at least one G551D mutation resulted in rapid and sustained weight gain, increased FEV\(_1\)%, decreased pulmonary exacerbations, decreased sweat chloride concentration reflective of increased CFTR activity, and improved patient reported health-related QOL outcomes\(^3^,4\). In the STRIVE study of 161 adolescents and adults (12+ years old), subjects gained 3.1 kg after 48 weeks of treatment compared to 0.4 kg for those on placebo\(^3\). In the ENVISION study of 52 younger growing children (6 to 11 years old)\(^4\), subjects gained 3.7 kg after 24 weeks of ivacaftor vs. 1.8 kg for placebo. In both studies, weight gain and improved lung function occurred rapidly with a weight plateau by 16 weeks or earlier. In people with non-G551 gating mutations (KONNECTION study, 6+ years old)\(^10\), BMI Z scores improved 0.24 after eight weeks of treatment compared to -0.04 for placebo. A long term ivacaftor open-label phase that followed the STRIVE and ENVISION studies (PERSIST study)\(^11\) as well as observational studies have shown persistence and stability of weight gain and improvement in nutritional status over two or more years\(^12,13\).

Ivacaftor has shown similar benefit in younger children and has been approved for use in 2 to 5 year old children. Ivacaftor was found to be safe and effective in 33 children in the KIWI study completed 24 weeks of treatment in the KIWI study, with significant reductions in sweat chloride concentration, and an average increase in weight Z score of 0.2±0.3 and BMI z score of 0.4±0.4\(^6\). Some exocrine pancreatic function restoration was demonstrated in these young children, as Davies et al.\(^6\) noted an increase in fecal elastase concentrations in a small sample of children after 24 weeks ivacaftor treatment. Prior to treatment, 93% were PI with fecal elastase concentrations of <50 µg/g, and after treatment this increased 100 µg/g on average. Furthermore, in the KLIMB study, a long-term follow-up to the KIWI study, the increased fecal elastase concentrations were sustained with mean increase of 129 µg/g after 84 weeks of treatment\(^14\). These results suggest that exocrine pancreatic function early in life may be partially restored with ivacaftor\(^6,15\).

In a recent open-label Phase 3 trial (the ARRIVAL study)\(^16,17\) in 18 children ages 1 to 2 years of age with CFTR gating mutations (G551D, G178R, S549N, S549R, G551S,
G1244E, S1251N, S1255P, G1439D, or R117H) who completed 24-weeks of treatment, ivacaftor was safe and effective in significantly reducing sweat chloride concentrations from 104.1 to 31.5 mmol/L, and improving (restoring) pancreatic function as indicated by increasing fecal elastase from 182 to 357 ug/g stool. Ivacaftor’s impact on growth status or velocity for weight and BMI in these young children was not reported. Changes in energy expenditure with ivacaftor treatment in these young children has also not yet been explored. This current application will directly address gaps in knowledge related to the important non-pulmonary outcomes that are clinically very important in very young children.

In our recent longitudinal observational study of 23 subjects (ages 5 to 61 years), we identified several mechanisms for weight gain with 3-month ivacaftor treatment including decreased resting energy expenditure (REE), gut inflammation and dietary fat malabsorption, resulting in a positive energy balance and weight gain. Weight gain in this study was 2.5 kg and was associated with a significant decrease in REE percent predicted of 5.5%, and in fecal calprotectin of 30 ug/g stool, a measure of gut inflammation. For the 16 subjects with PI, dietary fat absorption as measured by coefficient of fat absorption (CFA) improved 3%. Dietary fat intake increased significantly in all subjects, and energy intake increased, particularly in those from Italy. In subjects <20 years of age, improved weight and BMI status was accompanied by beneficial effects on muscle mass, muscle function and QOL. Improvement in pancreatic function (fecal elastase) was seen in 5 of 7 subjects with PS. Whether a similar improvement in REE, growth status and gut health and function related to improved fat absorption in young children with CFTR gating mutations is not known.

Several outcomes related to improved energy balance are considered in this proposal. Building on our results in older subjects, we will once again focus on the importance of determining the effect of ivacaftor treatment on clinically important non-pulmonary outcomes. Our primary aim in this study of young 1 to 2 year old children is to determine if 12-week ivacaftor treatment results in decreased sleeping energy expenditure (REE) and improved growth status by BMI Z score. Our secondary aim is to determine improvement in gut health and function associated with fat digestion, including increased total plasma fatty acids and fecal elastase, and decreased fecal calprotectin. Exploratory aims include investigating the impact of ivacaftor treatment on dietary intake, length, weight and head circumference status and growth velocity, and on serum fat soluble vitamins, bile acids and calprotectin.

In addition to reduced dietary fat absorption, altered fatty acid metabolism has been shown in CF and PI, and may be linked to CFTR dysfunction, and little is known of changes with CFTR modulator treatment. In the GOAL study, change in serum fatty acid concentrations with ivacaftor treatment were explored. Serum arachidonic acid levels decreased while linoleic and docosahexenoic acid levels did not change in 40 subjects with G551D CFTR mutation. We previously demonstrated a significant increase in total plasma fatty acids from 8.5±1.6 to 10.2±3.6 mmol/L (P<0.01) with 3-month treatment of a fat-based nutritional supplement: linoleic, lauric, palmitoleic, oleic and docosatetraenoic acids all significantly increased as well. We propose to assess a plasma fatty acid panel that includes concentrations for 22 individual fatty acids as well as total fatty acids, as an indicator of change in fat absorption.

Serum calprotectin is a marker for whole body inflammation including lung and gut inflammation in CF, and other chronic inflammatory diseases, and will be assessed along with fecal calprotectin. Improvements in length, weight and head circumference
status will likely result from an expected reduction in SEE in these children associated with ivacaftor treatment. Furthermore, comparisons of metabolic profiles in children with CF and their healthy counterparts, showed that the children with CF had profiles indicating bile acid processing abnormalities. Whether ivacaftor treatment results in improved fatty acid profiles, gut and systemic inflammation (fecal and serum calprotectin), bile acids and fat soluble vitamin status as markers of improved fat absorption in young children with CFTR gating mutations is not known and represent novel and clinically meaningful outcomes in young children with CF.

We propose a longitudinal study design to determine whether 12 weeks of treatment with ivacaftor results in improvement in SEE, growth status as BMI Z score, and gut health and function in 18 children ages 1 to 2 years with at least one CFTR gating mutation. There will be a mid-treatment evaluation at 6 weeks to explore the pace of the change in the primary and secondary outcomes. To plan the study, we assume that 1/3 of subjects will be recruited locally within a 150 mile radius of Philadelphia and the remaining 2/3 from other CF Centers in North America and will travel to Children’s Hospital of Philadelphia (CHOP) for three protocol visits, each visit lasting 2 or 3 days, conducted at our Center for Human Phenomic Science (CHPS) and Nutrition and Growth Laboratory.

The primary aims of this study are to determine whether ivacaftor treatment reduces SEE and increases BMI Z score. Secondary aims are to determine if ivacaftor treatment improves gut health and function resulting in better fat absorption as indicated by increased total plasma fatty acids and fecal elastase, and decreased fecal calprotectin. Exploratory aims are to examine the impact on dietary intake, growth status and velocity, serum fat soluble vitamins, serum bile acids, and serum calprotectin as a measure of systemic inflammation.

1.2 Compliance Statement

This study will be conducted in full accordance all applicable Children’s Hospital of Philadelphia Research Policies and Procedures and all applicable Federal and state laws and regulations including 45 CFR 46. All episodes of noncompliance will be documented.

The investigators will perform the study in accordance with this protocol, will obtain consent and will report unanticipated problems involving risks to subjects or others in accordance with The Children’s Hospital of Philadelphia IRB Policies and Procedures and all federal requirements. Collection, recording, and reporting of data will be accurate and will ensure the privacy, health, and welfare of research subjects during and after the study.

2 STUDY OBJECTIVES

We propose a longitudinal study design to determine whether 12 weeks of treatment with ivacaftor results in improvement in sleeping energy expenditure (SEE), growth status as BMI Z score, and gut health and function in n=18 children ages 1 to 2 years with at least one CFTR gating mutation. We anticipate that these changes will accompany meaningful improvements in dietary intake, growth status and growth velocity, and serum fat soluble vitamins, bile acids and serum calprotectin in these young children.
2.1 Primary Aims

H1: Ivacaftor treatment will result in a significant reduction in SEE as percent predicted over 12 weeks compared to baseline, thereby increasing the energy available for weight gain and physical activity.

H2: Ivacaftor treatment will result in significantly increased BMI Z score over 12 weeks compared to baseline.

2.2 Secondary Aims

H3: Ivacaftor treatment will result in significantly improved gut health and function resulting in better dietary fat absorption as indicated by increased total plasma fatty acids and fecal elastase and decreased fecal calprotectin over 12 weeks compared to baseline. To determine if treatment with Ivacaftor results in increased dietary fat absorption using three methods:

2.3 Exploratory Aims

1) To determine the impact of ivacaftor treatment over 12 weeks compared to baseline in:
   a) Dietary intake of calories and percent calories from fat
   b) Growth status for length, weight, head circumference and growth velocity
   c) Serum fat soluble vitamins A, D, E and K, bile acids, and calprotectin

3 INVESTIGATIONAL PLAN

3.1 General Schema of Study Design

3.1.1 Screening Phase

Subjects (n=18) will be recruited to participate in the study from a pool of subjects with at least one CFTR gating mutation. Given our previous success in enrolling subjects with CF from both local CF Centers and more distant Centers who traveled considerable distances to participate in our research protocols, we expect that enrollment will be achieved in a timely fashion. The plan to initiate treatment and the clinical eligibility for treatment is determined by the subject’s family and the CF care team.

Potential subjects will be screened using the protocol inclusion and exclusion criteria. The CF Centers around the country and Canada will provide the study with resources that will aide in recruitment efforts (i.e. to help to identify subjects with “gating” mutations). The subject’s CF care team will be contacted to confirm eligibility for the study and this will include obtaining medical information from the team and subject’s medical record. To collect medical data for screening purposes, a verbal or in person consent from parents/guardians will be obtained.

Parental/guardian permission (informed consent) will be obtained prior to any study related procedures being performed.

3.1.2 Study Enrollment Phase

Eligible subjects will be enrolled into the study and come to CHOP for the study visits. Refer to Table 1 for list of assessments and the study timeline for the pace of recruitment.

3.1.3 Follow-up Phase

Their initial baseline visit (Visit 1) will occur before clinically prescribed ivacaftor treatment has begun. The exact date of the start of medication will vary for families as they obtain
their medication. Subjects will return to CHOP for the 6 week visit (Visit 2) and the 12 week visit (Visit 3 and final) after subject/family has confirmed the timing of the start of ivacaftor treatment. There may be a delay between the baseline visit and the 6 week visit based upon when treatment begins. For most families, the total duration of the study will be from 4 to 6 months. The duration of the study from start of ivacaftor treatment until last study visit will be 12 weeks. For each of the 6 and 12 week visits following the start of ivacaftor treatment, there will be a window of ±2 weeks for the visit to occur (i.e. 6 week visit may occur between 4 and 8 weeks, and 12 week visit between 10 and 14 weeks post ivacaftor treatment).

Refer to Table 1 for list of assessments and the study timeline for the visit schedule.

### 3.2 Study Duration, Enrollment and Number of Sites

#### 3.2.1 Duration of Study Participation

The study duration for subject participation from enrollment to the last study visit will range from 4 to 6 months. The baseline visit will occur prior to the start of ivacaftor treatment. From the start of the clinically prescribed ivacaftor treatment to the last study visit will be 12 weeks with a window of ±2 weeks.

#### 3.2.2 Total Number of Study Sites/Total Number of Subjects Projected

The study will be conducted at one investigative site in the United States. Recruitment will stop when 18 subjects are enrolled. It is expected that 18 subjects will be enrolled to produce 16 evaluable subjects.

### 3.3 Study Population

#### 3.3.1 Inclusion Criteria

- Cystic fibrosis with at least one CFTR gating mutation of these ten (G551D, G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P, G1439D, or R117H).
- Age: 1 to 2 years of age
- In their usual state of good health
- A clinical decision has been made for subject to begin ivacaftor treatment.
- Family committed to the 4 to 6 month study protocol with visits to CHOP that will last 2-3 days for the baseline visit (Visit 1) prior to ivacaftor treatment and the 12 week visit (Visit 3) after clinically prescribed ivacaftor treatment has begun, and will last up to 2 days for the 6 week visit (Visit 2) after ivacaftor treatment has begun.
- Note that if ivacaftor is approved by the FDA for 1 to 2 year old children for the additional 28 CFTR mutations known to be responsive to ivacaftor potentiation, these will also be considered. With our limited sample size, the mutations that have shown the strongest improvement with treatment will be given priority for enrollment.

#### 3.3.2 Exclusion Criteria

- On parenteral nutrition
- Use of any inhibitor or inducer medications of cytochrome P450 (CYP) 3A
- Liver function tests elevated above 3x the reference range for age and sex
- Other illness affecting growth or nutritional status
- Other contraindications described for ivacaftor therapy
4 STUDY PROCEDURES

4.1 Screening

Subjects will be screened using the protocol inclusion and exclusion criteria. Written (in person) or verbal (via phone) parental/guardian permission will be obtained prior to scheduling any study screening related procedures. Informed written consent will be obtained at the baseline visit prior to conducting any research procedures.

All subjects will be enrolled in their usual state of good health defined as no hospitalizations, emergency room or unscheduled acute illness clinic visits, and with activity levels and food intake considered typical by the subject and their care provider for two or four weeks prior to the baseline visit.

4.2 Observational Period

Many of the protocol assessments could occur on any of the visit days (i.e. questionnaires, spot stool sample). Below is the best estimate of how each day will proceed. The baseline (Visit 1) and the 12 week (Visit 3) visit after ivacaftor treatment has begun are nearly identical with the exception of obtaining informed consent which will occur at Visit 1 Day 1 prior to any assessments being done or specimens being collected. For the 6 week (Visit 2) and 12 week (Visit 3) visits that will occur after confirmation of the timing of the start of clinically prescribed ivacaftor treatment, there will be a ±2 week window for the visit. (i.e. 6 week visit may occur between 4 and 8 weeks, and 12 week visit between 10 and 14 weeks post ivacaftor treatment). The description provided here applies to subjects who are not local to CHOP and who will be traveling to Philadelphia from other regions of the US and Canada and staying at a local hotel for one night (or two nights if needed for Visits 1 & 3). For non-regional families, Day 1 of each Visit is the day of arrival to CHOP and first night of their hotel stay. If the subject is local to CHOP, we will still require a Day 1 visit for in-person written consent for Visit 1, however, for Visits 2 and 3, Days 1 and 2 can be combined to complete study protocol procedures, and they will come in to CHOP from home for the major study protocol days: Day 2 for Visit 2 and Day 2 and again on Day 3 (if needed) for Visit 3.

4.2.1 Baseline visit (Visit 1)

Day 1

- Informed Consent/Assent will be completed in at CHOP Main CHPS
- Instructions in preparation for study procedures will be given
- Spot stool sample will be collected for Fecal Elastase I and fecal calprotectin (collected anytime)
- Questionnaires may occur on this day (see Day 2 for details)

Day 2

- Sleeping energy expenditure with morning nap (or afternoon nap if necessary)
• Blood draw for CBC, CMP, pre-albumin, bile acids, fatty acids, serum calprotectin, vitamin A (retinol), vitamin D (25(OH)D), vitamin E (α-tocopherol) and vitamin K (κK)
• Spot stool sample for fecal elastase and fecal calprotectin (if not collected on Day 1)
• Questionnaires: Health History
• Anthropometry: Length, weight, head circumference, skinfolds, circumferences
• Whole body DXA sleeping (with morning or afternoon nap)

Day 3 (if needed and expected for half of subjects)

• Whole Body DXA sleeping (with morning or afternoon nap) – if it was not performed on Day 2

Post Visit Follow Up

• 3-day weighed food records
• Begin clinically prescribed ivacaftor treatment after food records have been completed, and document the date that ivacaftor treatment was started

In Between Visits 1 & 2

• Maintain adverse events diary

4.2.2 6 week visit (Visit 2) after ivacaftor treatment has begun

Day 1

• Instructions in preparation for study procedures will be given
• Spot stool sample will be collected for Fecal Elastase I and fecal calprotectin (collected anytime)
• Questionnaires may occur on this day

Day 2

• Sleeping energy expenditure with morning nap (or afternoon nap if necessary)
• Whole body DXA
• Anthropometry: Length, weight, head circumference, skinfolds, circumferences
• Blood draw for fatty acids and serum calprotectin
• Spot stool sample for fecal elastase and fecal calprotectin (if not collected on Day 1)
• Questionnaires regarding interval health history, Adherence to ivacaftor, enzymes, medications, and Adverse events

---

Post Visit Follow Up

• 3-day weighed food records
• Maintain adverse events diary

---

In Between Visits 2 & 3

• Maintain adverse events diary

---

4.2.3 12 week visit (Visit 3) after ivacaftor treatment has begun

Day 1

• Instructions in preparation for study procedures will be given
• Spot stool sample will be collected for Fecal Elastase I and fecal calprotectin (collected anytime)
• Questionnaires may occur on this day

Day 2

• Sleeping energy expenditure with morning nap (or afternoon nap if necessary)
• Blood draw for CBC, CMP, pre-albumin, bile acids, fatty acids, serum calprotectin, vitamin A (retinol), vitamin D (25(OH)D), vitamin E (α-tocopherol) and vitamin K (ucOC)
• Spot stool sample for fecal elastase and fecal calprotectin (if not collected on Day 1)
• Questionnaires about interval health history, Adherence to ivacaftor, enzymes, medications, and Adverse events
• Anthropometry: Length, weight, head circumference, skinfolds, circumferences
• Whole body DXA (with morning or afternoon nap)

Day 3 (if needed and expected for half of subjects)
Whole Body DXA while sleeping (with morning or afternoon nap) – if it was not performed on Day 2

Post Visit Follow Up

- 3-day weighed food records
- Maintain adverse events diary until 3-day food records are completed

4.3 Unscheduled Visits

Due to the complexity of the study, no unscheduled visits will be permitted.

4.4 Subject Completion/Withdrawal

Subjects may withdraw from the study at any time without prejudice to their care. They may also be discontinued from the study at the discretion of the Investigator for lack of adherence to study treatment or visit schedules, or AEs. The Investigator or the Sponsor may also withdraw subjects who violate the study plan, or to protect the subject for reasons of safety or for administrative reasons. It will be documented whether or not each subject completes the clinical study. If the Investigator becomes aware of any serious, related adverse events after the subject completes or withdraws from the study, they will be recorded in the source documents and on the CRF.

5 STUDY EVALUATIONS AND MEASUREMENTS

5.1.1 Medical Record Review

Variables that will be abstracted from the medical chart (paper or electronic):

- Date of birth
- Sex
- CF genotype
- Medications
- History of liver disease, CF related diabetes, GI disease or abdominal surgery

5.1.2 Laboratory Evaluations

Plasma Total Fatty Acids: A total plasma fatty acid panel will be assessed (ARUP Laboratories) to measure change in status of 22 fatty acids.

Fat Soluble Vitamins: Serum vitamin A and vitamin E assessed at Craft Technologies Laboratories. Serum vitamin D determined using Liquid Chromatography-Tandem Mass Spectrometry (CHOP). As a measure of vitamin K status, % undercarboxylated osteocalcin (Gundberg Lab, Yale University) will be assessed.

Serum Bile Acids: Total serum bile acids and 14 bile acid concentrations will be assessed by liquid chromatography tandem mass spectrometry (ARUP Laboratories)

Serum Calprotectin: Serum calprotectin will be obtained as a marker of lung and gut inflammation using a Buhlmann MRP8/14 ELISA kit (Alpco, Salem, NH)).

Safety Assessment: As part of safety assessment, a comprehensive metabolic panel including the ALT and AST liver enzymes, complete blood count and serum pre-albumin will be assessed (CHOP Clinical Laboratory).
5.1.3 Study Assessments

Sleeping Energy Expenditure: The primary outcome for the assessment of energy expenditure is sleeping energy expenditure (SEE). Using indirect calorimetry, SEE and respiratory quotient will be assessed using a computerized metabolic cart Vmax ENCORE at each protocol visit while the child is asleep. SEE will be assessed in the morning if possible and careful note of previous feeding of the child, including the time of day, amount of food, and feeding interval prior to test. SEE is compared to predicted values derived from the World Health Organization that adjust for age, sex and weight\textsuperscript{26} and Schofield equations that adjust for age, sex, weight and length\textsuperscript{27}. SEE as kcal/d will also be assessed by adjusting for both fat free mass (FFM) and fat mass (FM) obtained from whole body DXA (see below).

Anthropometric Assessment: The outcomes for weight gain, growth and nutritional status will be length, weight, BMI, and head circumference Z scores. Measures of body composition will also be conducted to determine relative muscle and fat stores. All anthropometric techniques will follow those described by Lohman et al\textsuperscript{28}. Weight (0.1 kg) will be measured on a digital electronic scale (Seca, Munich, Germany), length (0.1 cm) on an infantometer, (Holtain, Crymych, UK), and head circumference (0.1 cm) using an insertion tape. Skinfold thickness will be measured (0.1 mm) at the triceps, biceps, subscapular, and supra-iliac sites with a skinfold caliper (Holtain, Crymych, UK) to assess subcutaneous fat stores. Mid upper arm circumference measured with a non-stretchable fiberglass tape (0.1 cm) (McCoy, Maryland Heights, MO). All measurements will be used to generate age-sex-specific Z scores for length, weight, BMI, head circumference, arm circumference, triceps and subscapular skinfolds using WHO reference data\textsuperscript{29,30}. Z scores for growth velocity will also be calculated for the 12 week period using the WHO reference data\textsuperscript{31}, and will provide a novel approach to growth response.

Body Composition: Total body composition, total FFM and FM and percent body fat (%FAT) and regional fat deposition, will be assessed by whole body dual energy x-ray absorptiometry (DXA). Whole body scans (Delphi A, Hologic, Inc., Bedford, MA) will be conducted at each protocol visit. DXA uses very low-dose x-ray exposures (3 mrem) and measurements are rapid, making this a suitable technique for use in children. Standard positioning and clothing techniques are used. Quality control scans are performed daily using a simulated L1-L4 lumbar spine made of hydroxyapatite encased in epoxy resin, and a whole body composition phantom. A difference of >1.5% from the standard will be deemed out-of-range requiring servicing by the manufacturer. Whole body will be assessed by DXA at baseline and 12 week protocol visits.

Fecal Elastase I: Pancreatic function will be assessed at both visits by obtaining spot stool samples with fecal elastase 1 to determine the level of pancreatic enzyme activity\textsuperscript{32,33}. Subjects will be provided with the stool collection kit and proper instructions and supplies, and will bring a stool sample back the next day. The stool sample will be stored at -20°C, and analyzed with an enzyme-linked immunosorbent assay kit sent to ARUP Laboratory (Salt Lake City, UT).

Fecal Calprotectin: Spot stool samples will be obtained to determine fecal calprotectin, a marker for gut inflammation (CHOP Laboratories), determined using a QUANTA Lite® ELISA kit.

Dietary Intake: Three day weighed food record will be obtained and calories, macro- and micro-nutrient content averaged over the three days. Families will be trained by staff and provided with scales, spoons and all supplies necessary for the collection of the dietary data. Detailed verbal and written instructions will be provided to ensure that the recording
procedures are clearly understood. Also assisting with this will come from the Center for Human Phenomic Science (CHPS) staff and Bionutrition Unit system\textsuperscript{34,35}. Dietary intake of all nutrients will be analyzed using Nutrition Data System for Research software version 2012 developed by the National Coordinating Center (NCC, University of Minnesota, Minneapolis, MN)\textsuperscript{36}.

**Health Questionnaire:** The questionnaire will be administered by interview by the research staff, and will consist of two sections. The Health History section has general questions about the subject’s health history including documentation of medical history, recent hospital admissions and illnesses, medications, and nutrient supplement use. A section describes aspects of environment such as household size, insurance for child and whether on Medicaid. In addition to family contact information (name, address, phone numbers), contact information from two non-household contacts will be collected to maintain contact with the subject in the event that the family cannot be contacted at their primary residence.

**Adherence:** Questionnaire at the 6 and 12 week in person visit regarding adherence to treatment will be administered. Phone calls will be made to all families at the 3 and 9 week time points and at the 12-week in person visit after ivacaftor treatment has begun to assess adherence to treatment, to trouble-shoot any barriers to adherence, and also to collect information on adverse events experienced within the past four weeks. Adherence to treatment with ivacaftor treatment and pancreatic enzyme medication use will be assessed.

**Adverse Events Diary:** Families will be asked about all adverse events for their child at the 12 week protocol visit and during the phone calls at 3 and 9 weeks, and rate by intensity (mild, moderate, severe). Serious adverse events will be reported as per various policies in a timely manner to CHOP IRB, and CHPS.

### 5.2 Safety Evaluation

As part of safety assessment, a comprehensive metabolic panel including the ALT and AST liver enzymes, complete blood count and serum pre-albumin will be assessed (CHOP Clinical Laboratory).

Dosing will likely be interrupted by the CF clinical care team in subjects with ALT or AST of greater than 5 times the upper limit of normal (ULN).

Subjects will be asked about all adverse events at the 6 and 12 week protocol visits and during the phone calls at 3 and 9 weeks, and rate by intensity (mild, moderate, severe). Serious adverse events will be reported as per various policies in a timely manner to CHOP IRB, and CHPS.

### 6 Statistical Considerations

#### 6.1 Statistical Methods

Analysis will begin with descriptive analyses of the study sample using means, standard deviations, medians, and ranges for continuous variables, and frequency distributions for categorical variables. Descriptive statistics and exploratory graphing such as frequencies, means, standard deviations, box plots, and scatter plots will be used to assess the normality of the data in terms of the presence of skew and/or outliers.

**6.1.1 Analysis of Primary & Secondary Aims**

**Data Analysis:** Analysis will begin with descriptive analyses of the study sample using means, standard deviations, medians, and ranges for continuous variables, and frequency...
distributions for categorical variables. Descriptive statistics and exploratory graphing such as frequencies, means, standard deviations, box plots, and scatter plots will be used to assess the normality of the data in terms of the presence of skew and/or outliers. **Primary Aims:** The goals of the primary aims of this study are to determine whether ivacaftor treatment improves SEE and BMI Z score. **Secondary Aims:** The goal of the secondary aim is to determine whether ivacaftor improves gut health and function as measured by total plasma fatty acids, fecal elastase and fecal calprotectin (ug/g stool). Analysis of efficacy for the primary and secondary outcomes will be based on change from baseline (before treatment) in SEE% predicted (Schofield), BMI Z scores, total plasma fatty acids, fecal elastase and fecal calprotectin. The differences between baseline and 12 weeks continuous outcomes will initially be compared using paired-t-tests if continuous variables are normally distributed and nonparametric tests (Wilcoxon sign rank) if they are not. Subsequently, mixed effects longitudinal models will be performed to assess change over all three time points (baseline, 6 and 12 weeks), adjusting for potential covariates such as age, sex, and adherence to treatment. Chi-squared tests will be used for comparison of categorical variables before and after ivacaftor treatment. Using similar methods, exploratory analyses will examine improvement in dietary intake of calories and fat, in growth status (weight, length, and head circumference Z scores) and growth velocity (both absolute and Z scores), serum fat soluble vitamins, bile acids, and calprotectin.

### 6.2 Sample Size and Power

**Sample Size and Power:** This is a longitudinal study of the effects of ivacaftor treatment on outcomes before and after 12-week treatment. The sample size of 16 subjects to complete the study has been determined as adequate to have the power to test the primary outcomes of decrease in SEE percent predicted value (7% change), an increase in BMI Z score of 0.3, and secondary outcomes of measures of gut health and function; an increase in plasma total fatty acids from 8.5 to 10.5 mmol/L, an increase in fecal elastase of 120 ug/g stool, and a decrease in fecal calprotectin (-30 ug/g stool change). Using STATA, power calculations were generated, with \( \alpha = 0.05 \), for paired data (n=16) within the same sample (before and after 12 weeks of treatment) using the changes described above for the primary outcomes and secondary outcomes.

**Primary outcomes:** A sample size of 16 subjects results in 86% power to see a decrease of 7% in **SEE** (i.e. from 115 to 108) with a standard deviation of the change of 9%, using a paired t-test two-sided significance level. We demonstrated a change of similar magnitude in REE in 24 subjects with CF gating mutation after 3-mo treatment with ivacaftor\(^7\). For growth status, 16 subjects will provide 85% power to detect an increase in **BMI Z score** of 0.3 with a standard deviation of 0.4. In the KIWI study of 2 to 5 year old children with CFTR gating mutation treated with ivacaftor for 24 weeks, a BMIZ score increase of 0.4±0.4 was demonstrated\(^6\). We showed a BMI Z score increase over 12 weeks of 0.3±0.4 in our recent study of 18 children (5 to 19 years) with 12-week ivacaftor treatment\(^7\).

**Secondary outcomes:** A sample of 16 subjects will provide 80% power to detect an increase in **total plasma fatty acids** from 8.5 to 10.5 mmol/L with a standard deviation of 2.8%, will provide 88% power to detect an increase in **fecal elastase** of 120 ug/g stool with a standard deviation of 150 ug/g stool, and will provide 85% power to detect a decrease in **fecal calprotectin** of 30 ug/g stool with a standard deviation of the change of 40 ug/g stool. We previously demonstrated a 3-month increase in plasma total fatty acids of this magnitude in subjects with CF receiving a fat-based nutritional supplement\(^19\). Davies et al\(^6\) demonstrated a change of 100 ug/g stool in fecal elastase with 24-week ivacaftor treatment in for 2 to 5 year old children with CFTR gating mutations in the KIWI study, and an even
greater increase of 164 ug/g stool fecal elastase was shown in 1 to 2 year old children participating in the ARRIVAL study16. We have previously demonstrated a 3-month decrease of 30 ug/g stool in fecal calprotectin with ivacaftor treatment in 5 to 61 year old people with CFTR gating mutations7. The standard deviations of 9% for SEE, 40 ug/g stool for fecal calprotectin, 150 ug/g stool for fecal elastase and 0.4 for BMI Z score are reasonable estimates of the variability expected in changes for these variables from our experience with 3-12 month changes in these measures in previous longitudinal clinical trials we have conducted for changes in children and adults with CF7,18,19,37,38. In addition, our recent experience with SEE measures in 1 year old healthy children showed a standard deviation of 8% in SEE percent predicted values39 (personal communication).

We plan for up to 12% attrition over the 12 weeks. By enrolling 18 subjects we can account for attrition and also allow for the possibility of greater variability in the SEE, BMI Z scores and gut health and function measures.

7 STUDY MEDICATION (STUDY DEVICE OR OTHER STUDY INTERVENTION)

7.1 Description

This is an observational study of subjects who will be assessed before and after ivacaftor use. The study will not provide the ivacaftor to the subjects. It will be clinically prescribed by the subject’s home CF care provider and the subject will not begin the ivacaftor treatment until after all Baseline (Visit 1) study visit procedures have been completed.

8 SAFETY MANAGEMENT

8.1 Clinical Adverse Events

Clinical adverse events (AEs) will be monitored throughout the study.

8.2 Adverse Event Reporting

Since the study procedures are not greater than minimal risk, SAEs are not expected. If any unanticipated problems related to the research involving risks to subjects or others happen during the course of this study (including SAEs) these will be reported to the IRB in accordance with CHOP IRB SOP 408: Unanticipated Problems Involving Risks to Subjects. AEs that are not serious but that are notable and could involve risks to subjects will be summarized in narrative or other format and submitted to the IRB at the time of continuing review.

9 STUDY ADMINISTRATION

9.1 Data Collection and Management

Data Management: The CHPS will work with the study team to create case report forms, set up REDcap database, and provide training for data entry and quality assurance. REDcap, a secure, web-based database, provides real time calculations, error detection and an automated export procedure for seamless data downloads to Excel, SAS and Stata. REDcap and all study computers are password protected and allow for storage of direct identifiers and de-identified data in a single database. Subjects will be assigned a unique identification number to insure confidentiality. Biological specimens are stored, identified using unique numbers in locked CHPS freezer. Routine backup to a secure server,
including images of forms, the main study database, and files created for analysis, and analysis programs will be archived daily. Source documents will be stored in locked cabinets in secure research facilities with locked doors and security alarm with 24 hour security guard response.

We will establish a database to store study data using standard software (e.g. RedCap). The database will be designed to perform automatic computations, such as exact age based upon birth date and date of exam, and averaging anthropometric measures, which are recorded in triplicate. Reports containing the number of subjects enrolled and data entered for each subject are generated and reviewed each month by the PI. The PI, or study staff, will review all data collection forms on an ongoing basis for data completeness and accuracy as well as protocol compliance. Following data entry, all primary and secondary endpoint data will be verified against original source documents. Data verification will be performed by someone other than the individual originally collecting and entering the data.

All subjects will be assigned a unique identification number that will be used to insure strict confidentiality. The databases are secured with password protection to insure confidentiality and security. The informatics manager receives only coded information which is entered into the database under those identification numbers. Electronic communication with outside collaborators involves only unidentifiable information. A master list containing PHI and subject ID number will be kept separate from the data forms and the database that will only have a study ID number. The master list will be on a separate password protected file on CHOP’s secured server. All source documents including case report forms, laboratory results, and subject study binders will be kept in secured locations on the 14th floor of the Roberts Center for pediatric Research. The file cabinets and the study-specific room will be locked with access to study personnel only, and the outer hallway is also locked with limited access to CHOP research personnel.

Routine backup to the main study database, files created for analyses, and analysis programs will be completed. The main study database will be archived on a daily basis and stored on a CHOP secured server. The Informatics Core of the CHPS will create case report forms, set up the database in RedCap, and provide oversight for data entry and quality assurance for this study.

There is no set time for destroying the information that will be collected for this study.

9.2 Confidentiality

Medical history information will be obtained at baseline. All of the materials collected are for research purposes only, and data will be kept in strict confidence. No information will be given to anyone without permission from the subject or parent/guardian of the subject. This will be stated in the consent form. Confidentiality is assured by use of identification codes. All data, whether generated in the laboratory or at the bedside, will be identified with a identification code unique to the subject.

To maintain confidentiality, private health information will be collected, accessed and stored in accordance with Institutional policies and HIPAA guidelines, including the use of multilevel password protection and enforcement of system user privileges on the database. To minimize the risk of disclosure, all direct identifiers will be removed as soon as possible and codes will be substituted for personal identifiers. Records of individuals are stored with ID numbers and a code with no discernible personal identifiers. Code lists and data files will be stored in separate, secure locations. Data will be accessed and stored on password-protected computers on the CHOP network. To maintain confidentiality, codes will be used
in the database, presentations and publications. The Investigator and other site personnel will not use such data and records for any purpose other than conducting the study.

9.3 Regulatory and Ethical Considerations

9.3.1 Data and Safety Monitoring Plan

Safety will be formerly monitored weekly by the study team and PI. The IRB and CHPS will also monitor safety. The study protocol will be carried out in accordance with OHRP and NIH guidelines and requirements. SAEs that are unanticipated, serious, and possibly related to the study will be reported to the IRB, CHPS, all members of the research team, the clinical care team, and sponsor in accordance with requirements.

9.3.2 Risk Assessment

There is minimal risk to the subject associated with delaying clinically prescribed ivacaftor treatment until all procedures for the baseline visit (Visit 1) have been completed.

The procedures in this study involve the potential risks related to the drawing of blood. The risks of drawing blood are rare, and minimal. There is a small risk of pain, infection and local irritation associated with the blood draw. However, this is considered a minimal risk and skilled pediatric research nursing staff will perform phlebotomy. Each subject will have approximately 18cc (approximately 1.2 tablespoons) of blood drawn at baseline (Visit 1) and 12 week (Visit 3) study visit, and 5 cc (1 teaspoon) at the 6 week visit (Visit 2), and no more than 5mL/kg over an eight week period.

There is minimal risk associated with the low radiation exposure from the DXA scan. Radiation exposure is estimated to be approximately 2.6 μSv per visit, well below everyday background exposure (approximately 8.2 μSv). DXA instruments are regularly monitored for safety, and only experienced pediatric research personnel will conduct these tests.

The sleeping energy expenditure assessment using the metabolic cart poses minimal risk to the subjects. There is minimal risk associated with anthropometric measurements, sharing dietary intake, demographic information, health history and medical information.

Collection and storage of stool is associated with a small risk of fecal contamination. However, for safety and convenience, subjects will be provided with proper stool collection instructions and supplies (gloves, disposable collection containers, storage freezer container).

Private health information will be collected, accessed and stored according to HIPAA guidelines, including the use of multilevel password protection and enforcement of system user privileges on the database. To minimize the risk of disclosure, all direct identifiers will be removed as soon as possible and codes will be substituted for personal identifiers. Records of individuals are stored with ID numbers and a code with no discernible personal identifiers. Code lists and data files will be stored in separate, secure locations. Data will be accessed and stored on password-protected computers. To maintain confidentiality, codes will be used in the database, presentations and publications.

If clinically significant results are found as a results of this research study, subjects/families will be informed and consent to share findings with their clinical care team will be obtained. Once consent to share medical information is obtained, the subject’s clinical care team will be contacted by the study team and the results transferred for appropriate follow-up.

In the event of a serious adverse event during the study protocol, it will be reported to Dr. Stallings (Principal Investigator), the IRB and CHPS, all study team members and sponsor.
as directed by policies and procedures and in accordance with requirements. With the approval of families, the information will be provided to their care providers as directed.

9.3.3 Potential Benefits of Study Participation

We cannot ensure a direct benefit to the subjects or their families as a result of participating in this study. Participants and their families may benefit from knowing that they will contribute to a clinical research study that is important to the health of people with CF in the U.S. and around the world.

9.3.4 Risk-Benefit Assessment

The research we propose is justified, considering that the risk associated with participation is minimal compared to the potential and anticipated benefits. The benefits of participation clearly outweigh the risks, in view of the positive and long-lasting benefits of the study to the larger population of people living with CF.

9.4 Recruitment Strategy

It is expected that all subjects will be recruited by word of mouth and at the recommendation of the subjects’ CF Care Team. The CF Foundation, CF Centers and CF support organizations around the country and Canada will provide the study with resources that will aid in recruitment efforts (i.e. to help to identify young subjects with “gating” mutations). Subjects will be recruited after introduction by the subject’s CF Care Team. Once a family has expressed interest in participating a CHOP-based research team member will contact the family via telephone or in person and continue the introduction of the study to families. Written (in person) or verbal (via phone) consent will be acquired to collect medical information to determine eligibility. For verbal screening consent, a waiver of documentation of consent, a waiver of assent and an alteration of HIPAA to obtain verbal consent and HIPAA authorization for screening over the phone will be in place. A waiver of verbal assent is requested due to the fact that the child is too young to provide it.

In the event that a non-English speaking family is approached for screening, an interpreter will be used either by phone or in person depending upon whether the screening takes place verbally over the phone or in person to present the study in a language understandable to the subjects/families. The interpreter can be conferenced into the phone call for the consent process. The screening consent will include the Study Summary Document for interpreter documentation attesting to statements on the summary document. This document will be faxed or emailed (using secure email) to the interpreter to sign and sent back electronically if the process takes place by phone. All members of the team will be available to discuss the details and answer any study related questions as they arise. Once interest and eligibility are determined, procedures to set up enrollment will begin.

9.5 Informed Consent/Assent and HIPAA Authorization

At entry into the study, parent(s) or legal guardian of the subjects will be asked to review the study informed consent form (ICF). The Project Coordinator or other member of the clinical research team will meet with the family on Day 1 of Visit 1 to review the form, to confirm the subject understands the study, and to answer any questions that the subject or parent/guardian might have. After all study-related questions are answered and subjects and families have had time to consider their decision, the Project Coordinator or member of the clinical research team will obtain fully informed, written consent from parent(s) or legal guardian of the subjects. Again, in the event of enrollment of a non-English speaking
subject/family, an interpreter will be used to present the study and the consent document in a language understandable to the family. The main ICF will include a Study Summary Document for interpreter documentation attesting to statements on the summary document. If the interpreter is not in person but is instead conferenced in by phone, then a copy of this attestation document will be faxed or emailed (using secure email) to the interpreter to sign and return to the team electronically. The consent will be signed in the presence of a team member. The families will be given a printed copy of the signed, informed consent. The subjects will be too young to assent to this study.

9.5.1 Waiver of Documentation of Consent/Assent and Alteration of HIPAA Authorization

Full waivers of consent will only be sought for the verbal screening component of the study. The rights and welfare of the subject will not be adversely affected because during the verbal consent process it is explained to the subject that we are recording their health information to determine eligibility for the study. Study staff stress during the verbal consent that the screening is voluntary, but necessary if they wish to participate, and that they can decline and stop the process at any point. A written informed consent will be obtained upon study entry before any study procedures are performed.

9.6 Payment to Subjects/Families

We will compensate subjects/families at a standard rate to offset incurred expenses, including compensation for time, food, and babysitting expenses. The baseline and 12-week visits will require 2 or 3 days and one or two overnight stays to complete the protocol. For the baseline (Visit 1) and 12 week (Visit 3) visits, we have assumed that half the families will receive $150 to complete the visit and study protocol procedures and half will require an additional day to complete procedures, and will receive $300. For the 6-week visit (Visit 2), all families will receive $150 as an additional day will not be an option. The average compensation to complete the study is $600, with a minimum of $450 and maximum compensation of $750. If the subject/family total compensation exceeds $600 in one calendar year, they will be provided with a W9 form.

<table>
<thead>
<tr>
<th></th>
<th>Each Visit</th>
<th>If Additional day required</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visit 1 (Baseline)</td>
<td>$150</td>
<td>$300</td>
</tr>
<tr>
<td>Visit 2 (6-weeks)</td>
<td>$150</td>
<td>$150*</td>
</tr>
<tr>
<td>Visit 3 (12 weeks)</td>
<td>$150</td>
<td>$300</td>
</tr>
<tr>
<td></td>
<td>$450 (minimum)</td>
<td>$750 (maximum)</td>
</tr>
</tbody>
</table>

*The compensation for Visit 2 (6 weeks) will always be $150 as there is no additional day option.

You will be compensated $150 for each visit for your time and effort associated with the study protocol procedures. Since two important tests (sleeping energy expenditures [SEE] and body composition [DXA]) for this Baseline Visit 1 require you to be very still, these are planned to be conducted during a nap. If the SEE and DXA are not completed in one day than an additional day may be needed. If subjects are not local to CHOP, they will stay in a nearby hotel for either 1 or 2 nights depending upon whether a Day 3 is needed to complete both the SEE and DXA. Subjects will also be reimbursed to cover the costs of
travel, parking and meals that have not been pre-arranged by the study team. Subjects/ families will provide receipts for these items. The 12-week Visit 3 plan is the same as Visit 1. The 6-week Visit 2 will be a two day visit.

For all subjects not from the Philadelphia area, we have assumed that the cost of travel will paid for the subject and one family member to accompany the subject for about half of the subjects and for two people to accompany the subject for the other half of subjects. The overnight stays will also be paid for the family at a hotel nearby to CHOP. Travel expenses that are considered reimbursable are: miles to/from CHOP for subjects who are traveling regionally (no further than New York or Washington, DC; miles to/from the airport or train station, parking at the airport or train station, cab to and from the airport or train station, checked bags. All expenses will be reimbursed with receipts by check request.

10 PUBLICATION

The research data obtained through the study outlined in this protocol will be shared with the research community, both through oral presentation at scientific meetings, and in written form, as published manuscripts. Reported factual material (primary data on which summary statistics and tables are based), commonly accepted in the scientific community as necessary to document and support research findings, will be provided in a timely fashion upon request by members of the scientific community to the principal investigator for a period of 3 years following acceptance for publication. The CHOP investigators will have access to the complete study data.
REFERENCES


16. Vertex Pharmaceuticals Inc. Vertex announces positive results from open-label phase 3 study of KALYDECO (ivacaftor) in children with cystic fibrosis ages 1 to 2


